RxDoctor Payments Data

Rose Stocker, DO

Family Medicine · Rockford, ILNPI 1407882038

Payments from drug & device makers

$1,351in general payments, 2019–2025

Across 28 payments — averaging $48.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$376
  • Johnson & Johnson$283
  • GSK$144
  • Dexcom, Inc.$125
  • Boehringer Ingelheim$122
  • Biohaven Pharmaceutical Holding Company Ltd.$119
  • plus $182 from 5 others

What the payments were for

  • Food & beverage$1,351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,351 in reported general payments places this provider in the 75th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$101,785
Medicare patients
319
Services billed
1,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$95,235
JanuviaSitagliptin Phosphate89$85,193
TrulicityDulaglutide65$75,851
JardianceEmpagliflozin65$75,574
MounjaroTirzepatide60$71,713
XareltoRivaroxaban56$56,828
EliquisApixaban48$52,201
Repatha SureclickEvolocumab31$29,802
Breo ElliptaFluticasone/Vilanterol39$22,080
TradjentaLinagliptin11$16,814
RybelsusSemaglutide11$14,218
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,856
Lantus SolostarInsulin Glargine,hum.Rec.Anlog82$11,510
GemtesaVibegron14$10,488
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$10,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$376$147,563125 claims
Novo NordiskOzempic, Rybelsus$54$109,45397 claims
Boehringer IngelheimJardiance, Tradjenta$122$92,38876 claims
MerckJanuvia$12$85,19389 claims
Johnson & JohnsonXarelto$283$56,82856 claims
GSKBreo Ellipta, Trelegy Ellipta$144$34,93659 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →